Diversity in Itraconazole Cocrystals with Aliphatic Dicarboxylic Acids of Varying Chain Length

被引:49
作者
Shevchenko, Anna [1 ,2 ]
Miroshnyk, Inna [1 ,3 ]
Pietila, Lars-Olof [2 ]
Haarala, Jorma [2 ]
Salmia, Jukka [2 ]
Sinervo, Kai [2 ]
Mirza, Sabiruddin [1 ,3 ]
van Veen, Bert [2 ]
Kolehmainen, Erkki [4 ]
Nonappa [4 ]
Yliruusi, Jouko [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Div Pharmaceut Technol, FIN-00014 Helsinki, Finland
[2] Orion Corp, Res & Dev, FI-02101 Espoo, Finland
[3] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA
[4] Univ Jyvaskyla, Dept Chem, Organ Chem Lab, FI-40014 Jyvaskyla, Finland
基金
芬兰科学院;
关键词
SOLID-STATE PROPERTIES; PHARMACEUTICAL CO-CRYSTALS; SOLUBILITY ADVANTAGE; CARBOXYLIC-ACIDS; DRUG; DISSOLUTION; IMPROVE; STABILITY; COMPONENT; BONDS;
D O I
10.1021/cg401061t
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The cocrystal formation potential of itraconazole, a potent antifungal drug, with C2-C10 aliphatic dicarboxylic acids has been investigated. Using two experimental screening techniques (solvent-assisted grinding and evaporation-based crystallization), the cocrystals of itraconazole with C2-C7 dicarboxylic acids have been successfully synthesized and characterized by powder X-ray diffraction, solid state nuclear magnetic resonance, Raman spectroscopy, and thermal analysis. The characterized multicomponent compounds include anhydrous cocrystals (malonic, succinic, glutaric, and pimelic acids), a cocrystal hydrate (adipic acid), and cocrystal solvates with acetone and tetrahydrofuran (oxalic acid). This study is the first to demonstrate the diversity in itraconazole cocrystals with a range of aliphatic dicarboxylic acids of variable carbon chain lengths.
引用
收藏
页码:4877 / 4884
页数:8
相关论文
共 54 条
[1]   Establishing Supramolecular Control over Solid-State Architectures: A Simple Mix and Match Strategy [J].
Aakeroey, Christer B. ;
Panikkattu, Sheelu V. ;
DeHaven, Baillie ;
Desper, John .
CRYSTAL GROWTH & DESIGN, 2012, 12 (05) :2579-2587
[2]   Avoiding "Synthon Crossover" in Crystal Engineering with Halogen Bonds and Hydrogen Bonds [J].
Aakeroy, Christer B. ;
Chopade, Prashant D. ;
Desper, John .
CRYSTAL GROWTH & DESIGN, 2011, 11 (12) :5333-5336
[3]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[4]  
[Anonymous], MOL OP ENV MOE 2012
[5]   Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals [J].
Babu, N. Jagadeesh ;
Nangia, Ashwini .
CRYSTAL GROWTH & DESIGN, 2011, 11 (07) :2662-2679
[6]   The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics [J].
Bak, Annette ;
Gore, Anu ;
Yanez, Evelyn ;
Stanton, Mary ;
Tufekcic, Sunita ;
Syed, Rashid ;
Akrami, Anna ;
Rose, Mark ;
Surapaneni, Sekhar ;
Bostick, Tracy ;
King, Anthony ;
Neervannan, Sesha ;
Ostovic, Drazen ;
Koparkar, Arun .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (09) :3942-3956
[7]   Pharmaceutical evaluation of early development candidates "the 100 mg-approach" [J].
Balbach, S ;
Korn, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 275 (1-2) :1-12
[8]   Ritonavir: An extraordinary example of conformational polymorphism [J].
Bauer, J ;
Spanton, S ;
Henry, R ;
Quick, J ;
Dziki, W ;
Porter, W ;
Morris, J .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :859-866
[9]   Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates [J].
Blagden, N. ;
de Matas, M. ;
Gavan, P. T. ;
York, P. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :617-630
[10]   Current directions in co-crystal growth [J].
Blagden, Nicholas ;
Berry, David J. ;
Parkin, Andrew ;
Javed, Hafsa ;
Ibrahim, Asim ;
Gavan, Pauline T. ;
De Matos, Luciana L. ;
Seaton, Colin C. .
NEW JOURNAL OF CHEMISTRY, 2008, 32 (10) :1659-1672